NASDAQ •
Healthcare •
Biotechnology •
Quote as of 06/22/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization8.66 mln
Float7.99 mln
Earnings Date08/28/2026
Piotroski F-Score
2
/ 9
Weak
Beneish M-Score
-2.1
Caution advised
1-Year Forecast
3.92
Transformational upside
Relative Strength
13
/ 100
Significantly lagging
Debt / Equity
0.00
Debt-free
ROE
-44.66
Deeply negative
Business Description
Immuron Limited is an Australian biopharmaceutical company focused on developing and selling antibody-based products that protect the digestive system, with operations across Australia, the United States, and Canada. Its consumer products include Travelan, which helps reduce the risk of traveler's diarrhea, and Protectyn, which supports liver and gut health. The company also has several treatments in clinical trials targeting intestinal infections caused by bacteria such as Campylobacter, E. coli, and Clostridium difficile, developed in partnership with US military medical research bodies. Founded in 1994 and headquartered in Carlton, Australia, Immuron has built its business around a core platform of immune-based therapies derived from antibodies.
